Immune cell 'Packages' injected into tumors: a new hope for advanced cancer?

NCT ID NCT07563972

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. The main goal is to check for side effects, but researchers will also watch for any tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mechanobiologically reprogrammed macrophage-derived exosomes
What this could lead to: If it works, this could point toward a new way to treat advanced solid tumors by reprogramming immune cells to attack cancer.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants, so safety and effectiveness are not yet known. The treatment is injected directly into tumors, which may not work for all cancer types or locations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS NEOPLASM

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.